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ABSTRACT 
 Depression is among the most common behavioral and psychological symptoms of dementia, 
and leads to more rapid decline and higher mortality. Treatment for depression in dementia has 
centered on conventional antidepressant drug treatment based around the monoamine hypothesis 
of depression. However, recent major studies have suggested that conventional antidepressant 
treatments that aim to correct underlying deficits in monoamine neurotransmitters are not 
effective for depression in dementia. Postmortem studies have also suggested that depression in 
dementia does not arise from serotonergic or noradrenergic abnormalities, or indeed from the 
degenerative pathology associated with Alzheimer’s disease. In contrast, considerable recent 
evidence has suggested that alterations in glutamatergic transmission may contribute to the 
pathophysiology of depression. This supports the view that treatment-resistant depressed 
patients, such as many dementia patients, may benefit from agents affecting glutamate 
transmission. This review will thus draw together the wealth of pathological data examining the 
basis of depression in Alzheimer’s disease and relate this to current thinking on treatment, with 
the aim of generating discussion on potential novel therapeutic strategies.  
 
Keywords: Alzheimer’s disease, antidepressants, cognitive impairment, dementia, depression, 
late-life  
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INTRODUCTION 
 Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting an estimated 
35.6 million people worldwide [1]. While AD is mainly characterized by progressive memory 
loss, as well as deficits in orientation, spatial awareness comprehension, and language, the 
frequently occurring non-cognitive symptoms of dementia, termed the behavioral and 
psychological symptoms of dementia (BPSD), have gained increasing recognition due to their 
substantial physical, emotional, and financial impact on patients and their carers [2]. Depression 
is one of the most common BPSD, occurring in about 20% of AD, 30% of vascular dementia, 
and 40-50% of dementia with Lewy bodies patients, where its high prevalence has led to it being 
added as a supportive diagnostic feature [3]. The presence of depression in dementia has been 
associated with more rapid decline [4], higher mortality [5], and earlier institutionalization [2]. 
Reciprocally, depression in late-life is frequently accompanied by deficits in performance in 
aspects of cognitive function [6], with an increased risk of mild cognitive impairment (MCI) 
associated with depressive symptoms over time [7]. While depression in dementia is not 
currently recognized as a single clinical entity, a substantial body of pathophysiological and 
epidemiological data suggest depression and dementia seem inextricably linked [8-10] and likely 
share risk factors and common pathophysiological pathways [11, 12]. Several cross-sectional and 
longitudinal studies have found an association between late-life depressive symptoms and 
subsequent cognitive decline to MCI and dementia [12-14]. A recent systematic review and 
meta-analysis found a two-fold increase in risk of dementia in depressed patients [15], and it has 
been suggested that greater than 10% (nearly 3.6 million) AD cases worldwide could be 
attributed to depression [16]. Such findings suggest the symptomatic manifestation of depression 
is not merely a psychological reaction to the awareness of dementia but may derive from 
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neurobiological changes in common brain areas, which may act as either prodromal state 
preceding impending cognitive deficits, or an independent risk factor for the development of AD. 
The possible differences in the pathogenesis of late-life depression in dementia, when compared 
against depression in younger patients, may also explain the apparent lack of efficacy of 
conventional antidepressant drug therapy for depression in dementia. Recent findings from two 
major studies [17-19] have suggested that, contrary to previous belief, monoamine-based 
antidepressant treatment is not effective for depression in dementia. The poor prognosis and the 
lack of knowledge into the etiological and neurobiological processes has highlighted the urgent 
need for research into the pathological and molecular correlates of the causes of depression 
within the context of dementia. This review therefore seeks to appraise the current knowledge of 
the neuropathological and neurobiological causes of depression in AD, with the aim of offering 
potential avenues for antidepressant treatment.  
 
THE PATHOPHYSIOLOGICAL BASIS LATE-LIFE DEPRESSION 
Neuroanatomy 
 Early primate studies identified networks of limbic, striatal, and prefrontal brain regions 
associated with affective function [20-22]. These findings have been supplemented by clinical, 
neuroanatomical, and imaging studies, which have helped characterize the behavioral, cognitive, 
and visceral manifestations of mood disorders [23-25]. Five segregated, parallel striatal-
thalamocortical circuits have been delineated in primates, three of which have been associated 
with cognitive and emotive function in humans: the anterior cingulate cortex (ACC)-nucleus 
accumbens (ACC circuit), dorsolateral prefrontal cortex (DLPFC)-head of caudate nucleus 
(DLPFC circuit), orbitofrontal cortex (OFC)-head of caudate nucleus (OFC circuit) circuits [20]. 
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The DLPFC circuit is associated with regulating executive functions, such as problem solving, 
organization, working memory, and intellectual function and action [25, 26]. The OFC circuit is 
thought to integrate limbic and emotional information into behavioral response, and is involved 
in sensory integration [27]. The ACC circuit is an important component of reward and 
motivational systems in the brain. Lesion studies have shown that akinetic mutism is closely 
related to lesions to the ACC [28], manifesting as a wakeful state of profound apathy, with 
indifference to pain, thirst, or hunger. 
 Findings from numerous imaging and postmortem morphological studies have led to a 
reappraisal of the pathophysiological basis of major depression in late-life, suggesting that 
neurodegenerative and vascular mechanisms may play a significant part in the manifestation of 
symptoms [29]. Multiple structural magnetic resonance imaging (MRI) data have revealed 
volumetric reductions in grey matter structures associated with affective function, including the 
hippocampus [30, 31], OFC [32-34], caudate nucleus [35, 36], and amygdala [37]. Furthermore, 
a recent systematic meta-analysis of 17 MRI studies examining volumetric changes in brain 
regions associated with affective function revealed significant volume reductions in the OFC, 
putamen, and thalamus in patients with late-life depression [38]. Neuroimaging studies have also 
found increased white matter hyperintensities in several key areas involved in affective circuitry 
in late-life depression patients. Hyperintensities are more common in late-life depression than in 
younger patients [39, 40] or control subjects [39, 41]. Large-scale cross-sectional studies have 
also reported that basal ganglia lesions [42] and subcortical white matter changes [43] are 
associated with depression, especially in the elderly. However, as imaging remains hampered by 
limitations in spatial resolution, which precludes the measurement of cellular components in 
circuitry involved in affective regulation, postmortem neuromorphometry studies have offered 
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the most suitable approach for the identification of discrete changes in the brain microstructure in 
depression.  
 
Neuropathology 
 Advances in stereological methodology, e.g., the ‘optical disector’ (for the measurement of 
particle density) and the ‘nucleator’ (for the measure of particle volume) techniques, as well as 
technology, with the advent of sophisticated computer-based image analysis methods, has 
allowed the reliable assessment of potential alterations in neuronal and glial cell populations in 
postmortem tissue taken from depressed patients. In general, studies conducted in cortical tissue 
taken from younger or mixed-age groups have revealed regional-specific decreases in packing 
density of glial cells in the DLPFC (BA 9) [44], subgenual [45], and supragenual [46] ACC and 
rostral OFC (BA 47) [44]. Such findings appear to contrast with studies conducted in tissue taken 
from cortical areas from patients exclusively aged 60 years or over, where no changes have been 
found in glial cell density in the DLPFC (BA 9) [47], caudal OFC (BA 11) [48] or subgenual 
ACC [49].  
 Unlike the disparity in glial cell pathology between the marked reductions in younger and 
mixed-age depression groups and the notable preservation in older patients, pathological changes 
to neurons appear more discrete and of a more similar magnitude between younger and late-life 
depressed patients. A study examining neuronal density in all six layers of the rostral OFC (BA 
47) found significant reductions in layers 3 and 5 in late-life depressed patients [44]. The study 
also found a negative correlation between age and overall density in both depressed and control 
groups. However, these findings were not replicated in a subsequent study in late life depression 
in the caudal OFC (BA 11) [48]. In the DLPFC, evidence of pyramidal cell pathology was found 
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through a reduction in volume through all layers, specifically in layers 3 and, more prominently, 
layer 5 [47]. However, again, these findings were not replicated; no changes were found in 
neuronal morphology in the DLPFC in depressed patients versus control [50]. No neuronal 
changes have been found in late-life depression in the subgenual ACC [49].  
 A greater degree of inconsistency has been found in neuronal morphology in the subcortical 
structures in depressed patients than cortical regions. Significant increases in neuronal density 
have been noted in the CA1-CA3 subfields of the hippocampus, as well as the dentate gyrus, 
with corresponding decreases in neuronal cell body volume [51]. These findings were not 
replicated in a more recent study [52]; however, the study did report a decrease in total 
hippocampal volume in a subset of recurrent/chronic depressed patients and an increase in 
pyramidal cell density with duration of depressive illness in the CA1 subfield, as well as an 
increase in granule cell and glial cell density in the dentate gyrus in patients taking 
antidepressant drugs [52]. Such findings may indicate an antidepressant medication-related 
increase in dentate gyrus granule cell proliferation. However, recent findings dispute such an 
effect [53]. Furthermore, a study of other limbic regions found no significant difference in 
neuronal density was found in the amygdala and entorhinal cortex in late-life depressed patients 
versus age-matched controls [54]. However, a significant reduction was found in glial cell 
populations in the amygdala [54]. A significant reduction in neuronal density, but not volume, 
has been found in the head of caudate nucleus. Reductions found in both the dorsomedial and 
ventrolateral aspects of the caudate nucleus, may have functional relevance due to connectivity 
with cortical affective circuitry. Pyramidal projection neurons emanating from layer 5 of the 
DLPFC and OFC send afferents to dorsomedial and ventrolateral aspects of the caudate nucleus, 
respectively. Thus, selective damage to pyramidal neurons in layer 5 of the DLPFC [47] and 
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OFC [44] may indicate disturbances in affective frontal-subcortical circuitry signaling in late-life 
depression [55]. Such changes are in accordance microstructural alterations described earlier in 
the white matter adjacent to the prefrontal cortex [56-59]. Diffusion tensor imaging-based 
investigation has also revealed increased mean diffusivity in prefrontal areas in late-life 
depression, indicating impaired white matter tract integrity [58]. Furthermore, a large 
neuroimaging study has reported a significant correlation between increased white matter lesion 
volume (particularly in frontal areas) and reduced caudate nucleus volume in late-life depression 
[60]. Taken together, these findings indicate that the dorsal prefrontal-striatal, as well as 
reciprocal thalamocortical, axonal tracts mediating affective function, may be particularly prone 
to damage from extraneous factors, such as vascular or inflammatory events [55]. Accordingly, 
the presence of white matter hyperintensities has been correlated with ischemic pathology. Deep 
white matter hyperintensities were identified and examined microscopically and while some 
lesions in controls cases were likely to be non-ischemic in origin, all hyperintensities in late-life 
depressed cases were demonstrated to be ischemic and most apparent in the DLPFC [61]. 
However, periventricular lesions were found to be of a non-ischemic origin and more likely a 
result of disruption of the ependymal lining of the ventricles [62].  
 
Neurobiology 
 The hypothalamic-pituitary-adrenal (HPA) axis is a major part of the neuroendocrine system 
that modulates stress response. Depression has long been associated with hypercortisolemia 
(such as found in Cushing’s syndrome), non-suppression on the dexamethasone test, increased 
vasopressin production in cells of the hypothalamic paraventricular nucleus, and loss of circadian 
rhythm regulating HPA function [63]. Moreover, aging itself has been shown to produce a 
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similar pattern of events [64], meaning HPA dysfunction is heightened in late-life depression 
[65]. Animal studies have revealed that the hippocampus is specifically prone to the toxic effects 
of prolonged glucocorticoid exposure [66]. The hippocampus contains the highest concentration 
of glucocorticoid and mineralocorticoid receptors in the brain, which are critical regulators of 
dendritic spine development and plasticity [67]. Glucocorticoids also alter expression and 
signaling of the neurotrophin, brain-derived neurotrophic factor (BDNF). As BDNF has been 
shown to promote neuroplasticity, cell survival, hippocampal neurogenesis, and cellular 
excitability, it has been hypothesized that specific adverse effects of glucocorticoids may be 
mediated via BDNF expression and signaling events [68]. Thus, higher cortisol levels have been 
shown to lower BDNF in the hippocampus, with antidepressants reversing the change [69]. 
Furthermore, in the absence of concomitant stress exposure, glucocorticoid exposure has been 
shown to result in memory disturbance [70-72]. Hippocampal atrophy has been frequently 
reported in depression in the elderly [73, 74] and amnesic deficits are prominent feature in late-
life depression on detailed cognitive assessment. Thus, a speculative link could be made between 
HPA dysfunction and the amnestic aspects of late-life depression. However, at least partial, 
recovery of the brain atrophy has been shown to occur following cessation of corticosteroid 
administration [75, 76]. Thus, the atrophy observed in hypercortisolemia cannot be deemed 
comparable with that found neurodegenerative disorders, and may represent a contributory rather 
than a causative factor in hippocampal damage and corresponding memory impairment [63]. 
 
THE PATHOLOGICAL BASIS OF AD 
 Senile plaques and neurofibrillary tangles (NFTs) are considered the key pathological 
hallmarks of AD. Early studies identified the presence of amyloid-β (Aβ) in tightly-packed 
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deposits in the brain parenchyma and vessel wall [77, 78], coupled with genetic studies 
identifying mutations in genes encoding amyloid-β protein precursor (AβPP) [79] and later those 
for presenilin 1 and 2 [80], were proposed to result in Aβ-containing plaques and the 
development of early-onset familial dementia. Such findings were incorporated into the 
‘Amyloid Cascade Hypothesis’, which postulated Aβ deposition as the initial pathological event, 
leading to the formation of senile plaques and then to NFTs, neuronal cell death, and ultimately 
dementia [81]. Particular cleavage of AβPP by secretase enzymes is thought to induce Aβ plaque 
formation. When AβPP is first cleaved by β-secretase, followed by γ-secretase, the Aβ1-40 or Aβ1-
42 molecule is produced via the amyloidogenic pathway, with the Aβ1-42 variant less soluble and 
more toxic [82]. Amyloid monomers aggregate to form toxic soluble oligomers, believed to 
mediate perturbation of synaptic connections and network dysfunction, and are associated with 
dystrophic neurites, activated microglia, and reactive astrocytes [83, 84]. Extracellular Aβ-
containing plaques follow stereotypical patterns of pathological progression, beginning 
exclusively in the neocortex, then spreading to allocortical brain regions, the diencephalic nuclei, 
striatum, and cholinergic nuclei and affecting the brainstem and cerebellum later in disease 
progression [85, 86]. NFTs are formed from the intracellular aggregation of the 
hyperphosphorylated microtubule-associated protein, tau. In normally functioning neurons, tau 
stabilizes microtubules forming the cellular cytoskeleton through the process of phosphorylation 
and dephosphorylation. Aβ interacts with signaling pathways that regulate the phosphorylation 
of tau [87], resulting in a hyperphosphorylated state and the polymerization with other tau 
molecules. In this pathogenic state, paired helical filaments are formed, which result in the 
accumulation of NFTs and toxic species of soluble tau, thus impeding normal neuronal function 
by disrupting axonal transport and eventually leading to cell death [88, 89]. As with plaque 
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formation, NFTs have a well-recognized pattern of progression in AD, with neurofibrillary 
pathology progressing from the transentorhinal to entorhinal and hippocampal, and finally the 
neocortical regions [85, 90].  
 While Aβ has been shown to play a fundamental role in AD pathogenesis, it remains unclear 
whether it is a primary driver in the disease trajectory. For instance, Aβ plaque density does not 
correlate with the severity of dementia [91, 92]. Furthermore, though it is widely assumed that 
NFTs are intrinsically involved in AD pathogenesis, there remains insufficient evidence to 
implicate them as the instigator of the neurodegenerative process. Indeed, some have speculated 
that Aβ plaque aggregates [93] and NFTs [94] may actually play a protective role, manifesting as 
a result of adaptive mechanisms to preserve endangered neurons. The apparent latency period 
between the appearance of AD pathology and clinical symptomatology has suggested that Aβ 
accumulation and NFT may occur upstream in the disease process, combining to trigger, or occur 
in tandem to, synaptic dysfunction, which may lead to cognitive impairment directly or indirectly 
via neurodegenerative processes [95].  
 Vascular dysfunction has long been known play a significant role in the pathophysiology of 
both AD [96, 97] and late-life depression [98, 99]. Preclinical and clinical imaging data has 
suggested deterioration of vasculature may precede cognitive decline and morphological changes 
in neuronal populations in AD. The lack of clearance of Aβ leads its accumulation in blood 
vessels and parenchyma. The resulting pathological state, cerebral amyloid angiopathy (CAA), is 
associated with cognitive decline and is one of the major hallmarks of AD pathology, occurring 
in >90% of AD-type dementias [96, 100] CAA lesions are thought to originate in the occipital 
lobe, followed by the frontal lobe, temporal lobe, and parietal lobe [101-104]. White matter 
lesions, frequently resulting from ischemic insult, commonly occur in patients with suspected 
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CAA, and are more marked in individuals with cognitive impairment [105]. Subcortical 
cerebrovascular disease may contribute to cognitive and behavioral deficits, via infarct damage 
located in frontal-subcortical circuitry, detailed earlier [20-22]. Furthermore, Binswanger’s 
syndrome has been postulated to cause slow, progressive cognitive impairment through 
hypoperfusion and demyelination of the deep white matter [106, 107]. Thus, it could be 
postulated that subcortical atrophic changes resulting from CAA could represent a potential 
mechanistic point of intersection between AD and late-life depression. Nevertheless, the lack of 
systematic studies assessing the possible psychiatric impact of CAA [108] has highlighted the 
considerable need for studies examining this relationship.  
 
DEPRESSION, MILD COGNITIVE IMPAIRMENT, AND DEMENTIA: A SIMILAR 
DISEASE TRAJECTORY?  
 Putative neuropathological links between late-life depression, MCI, and AD have been 
established from several angles. Such findings have supplemented clinical and epidemiological 
data that has placed depression in a continuum of events, either as a prominent risk factor or 
early manifestation of AD. AD patients with a history of major depression have been shown to 
have a greater number of hippocampal neuritic plaques and NFTs at autopsy than AD patients 
who had not experienced depression during life [109]. AD patients with a history of depression 
also demonstrated a more rapid cognitive decline than those who did not [109]. The presence of 
pathological hallmarks of AD, as well as α-synuclein and cerebrovascular pathology, has been 
demonstrated in late-onset depressed patients with a varying degree of cognitive impairment 
[110]. Imaging of Aβ deposits using the Pittsburgh compound-B radiotracer (PiB) has revealed 
that tracer retention in half of depressed subjects with MCI (3 if 6) fell within the range of AD 
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patients. PiB retention was comparable in two depressed subjects with normal cognitive ability 
and non-depressed cognitively normal subjects [111]. A further study using 2-(1-
[112]ethylidene) malononitrile ([(18)F]FDDNP) positron emission tomography to label amyloid 
and tau protein binding revealed significantly higher binding in the posterior cingulate and lateral 
temporal regions in late-life depressed patients [112]. Sun and colleagues elaborated on Aβ 
involvement in late-life depression by examining the ratio between Aβ40 and Aβ42 plasma 
peptide [11]. Previous data [113, 114] has revealed that low concentration of Aβ42 combined 
with high Aβ40 levels increases the risk of developing AD. Accordingly, Sun et al. [11] found 
that late life-depression subjects had lower plasma Aβ42 levels and a higher Aβ40:Aβ42 ratio than 
age-matched controls, in the absence of cardiovascular disease or antidepressant treatment. 
Depressed subjects with a high Aβ40:Aβ42 ratio also had greater impairment in memory, 
visuospatial ability, and executive function, whereas depressed patients with a more comparable 
Aβ ratio did not have significant memory deficits [11]. Nevertheless, several pathological studies 
have failed to associate cognitive impairment in depression with plaque or tangle pathology 
[115-117], and it is likely that cognitive aspects of late-life depression arise from several inter-
related pathophysiological mechanisms, which result in a wide-range of deficits requiring 
focused treatment strategies.  
 
MONOAMINERGIC SYSTEMS IN DEPRESSION AND AD 
 Changes to subcortical nuclei have long been thought to play a primary role in late-life 
depression and AD pathogenesis. AD is associated with degeneration of subcortical populations, 
particularly cholinergic and monoaminergic systems. Long and poorly myelinated axons, which 
project extensively to hippocampal and cortical regions, are particularly prone to damage in AD 
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[118]. Early reports noted significant reductions in nucleolar volume and total RNA levels in 
both serotonergic and norepinephrinergic neurons in the brainstem of AD patients [119, 120]. 
Moreover, a reduction in inhibitory G-protein-linked 5-HT1A receptors has been found in 
postmortem hippocampal tissue taken from AD patients with depression [121]. Selective 
vulnerability of brainstem monoaminergic nuclei has been demonstrated in AD, with the rostral 
raphè especially prone to tangle formation, whereas others exhibit plaque and tangle expression 
[122]. Nevertheless, several studies examining late-life depression within the context of AD have 
proved more equivocal, with pathological changes frequently not varying between AD patients 
with depression and those without. A consistent loss of 5-HT neurons has been found in AD 
patients [115, 123]. However, when these patients were subdivided into depressed and non-
depressed groups, no difference in the number of neurons was found between the two groups 
[115]. Similarly, though reductions in the binding of protein that aids the function of 5-HT, the 
5-HT transporter, have been found in AD no greater reductions were found between the AD 
groups with depression and those without [124]. Furthermore, although a significant loss of 
norepinephrinergic pigmented neurons was found in the locus ceruleus in AD, no supplementary 
loss of neurons was found in patients with depression and AD [125]. A recent study also found 
no association between brainstem tangles and depressive symptoms. However, a lower density of 
tyrosine hydroxylase-immunoreactive neurons in the ventral tegmental area was associated with 
higher level of depressive symptoms, suggesting a role for the mesolimbic dopamine system in 
late-life depressive symptoms. The mesolimbic dopaminergic ventrotegmental-nucleus 
accumbens pathway plays a crucial role in reward and associations have been made between 
components of the circuit and mood regulation (for a detailed review, see Nestler and Carlezon, 
[126]). However, postmortem studies of the dopaminergic system in depression have been scarce 
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and, perhaps unsurprisingly, have provided conflicting results. Nevertheless, given the high 
prevalence of depression in neurodegenerative disorders significantly affecting dopaminergic 
transmission—depression occurs in 50-60% in dementia with Lewy bodies and Parkinson’s 
disease [127], and is more common and persistent than in AD [128]—further consideration of 
the role of dopamine in affective dysregulation in neurodegenerative disorders is warranted.  
 Despite the lack of clear evidence linking pathological changes in monoaminergic nuclei and 
late-life depression, especially within the context of dementia, treatment strategies for depression 
in AD mirror the treatment of depression alone, stemming from Schildkraut’s 1965 
‘catecholamine hypothesis of depression’ [129]. Modern selective serotonin reuptake inhibitors 
(SSRIs), such as sertraline, remain the first-line of treatment for depression in dementia. Until 
recently, it was unclear whether such conventional monoaminergic agents would be as effective 
in patients for depressive symptoms in dementia as they are in patients without dementia. 
However, two recent major studies have suggested that this is not the case. The DIADS-2 study 
compared the commonly-used SSRI antidepressant sertraline (n=67) with placebo (n=64) in 
depression in AD patients and found no significant change in symptoms, response, or remission 
rates after 12 [18] or 24 weeks [19]; moreover, they found evidence that the treatment resulted in 
an increase in the risk of adverse events and thus concluded that this drug was not suitable for 
depression in AD [18, 19]. The UK-based SADD study [17] also found sertraline and another 
class of antidepressant drug, the noradrenergic and specific serotonergic antidepressant 
mirtazapine, to be ineffective, when compared against placebo, and were again associated with 
an increase in adverse effects.  
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THE ROLE OF GLUTAMATERGIC SIGNALLING IN THE PATHOPHYSIOLOGY OF 
DEPRESSION  
 The lack of clear evidence of pathological change in monoaminergic circuitry in brain tissue 
taken from late-life depressed patients per se or in the context of AD, coupled with the 
ineffectiveness of monoaminergic agents, has suggested the need for a reappraisal in research 
and treatment strategies for depression in dementia. Considerable interest has recently been 
expressed in the potential use of agents affecting the main excitatory neurotransmitter in the 
brain, L-glutamic acid (glutamate). Glutamate signaling occurs at both pre- and post-synaptic 
sites through both ionotropic and metabotropic receptors [130]. Ionotropic glutamate receptors, 
which are highly permeable to Na+ and Ca2+, are the principal mediators of fast excitatory 
neurotransmission in the central nervous system [130]. Three subfamilies of ionotropic receptors 
have been identified: alpha-amino-3-hydroxy-5-methylisxazole-4-propionic acid (AMPA), 
kainate, and N-methyl-D-aspartate (NMDA) receptors. The modulation of the NMDA receptor 
complex and its associated molecular mechanisms related to synaptic and neuronal plasticity 
have prompted a new generation of disease models of depression and antidepressant therapeutics 
[131-134]. Numerous imaging and postmortem studies have highlighted glutamatergic 
abnormalities in major depression patients. Magnetic resonance spectroscopy studies have 
reported heightened cortical glutamate levels in major depression [135, 136]. Postmortem studies 
have demonstrated elevated glutamate levels in the frontal cortex and a significant 
downregulation in mRNA transcripts for vesicular glutamate transporters and excitatory amino 
acid transporters [137], which are vital for the rapid removal of glutamate from synapses. This is 
reflected in altered post-synaptic receptor binding and expression of NMDA, and AMPA/kainate 
receptors in major depression [137, 138]. Preclinical models have also suggested the NMDA-
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mediated events are fundamental in the pathogenesis of depression and its treatment. Inescapable 
stress has been shown to disrupt hippocampal neuronal long-term potentiation, which is 
regulated through NMDA receptor activation. Considerable preclinical evidence has also 
demonstrated the importance of glycine recognition sites on NMDA receptors in the regulation 
of anxiety-related behaviors [139]. Accordingly, several functional antagonists of the NMDA 
receptor, including ligands at the glutamate, glycine, polyamine, vivalent cation (Zn2+), and 
ionophore recognition sites, have been shown to exert fast-acting antidepressant and anxiolytic 
effects in animal models [140]. Furthermore, other preclinical model studies suggest that 
chronic, but not acute, administration of conventional monoamine-acting antidepressants 
modulate NMDA receptor activity, suggesting that post-receptor downstream neuronal 
adaptation processes, rather than the direct effects of extracellular synaptic monoamine levels, lie 
behind the therapeutic effect [141].  
 Increasing evidence has suggested that the clinical symptomatology of AD arises from 
morphological changes and associated deficits in synaptic function, which may begin several 
years prior to neuronal loss. Markers of synaptic degeneration have been consistently found to 
correlate with cognitive dysfunction [142, 143]. Abnormalities in vesicular proteins, including 
synaptobrevin, synaptotagmin, and Rab3a [144], as well as pre- and post-synaptic proteins, such 
as synaptophysin [145], drebrin [146], neurogranin, and synaptopodin [147] in the various brain 
regions of AD patients. Biochemical studies have indicated impaired glutamatergic transmission 
in AD. Early antemortem and postmortem studies revealed reductions in glutamate concentration 
in AD patients [148-151]. Furthermore, reductions in the expression of NMDA and AMPA, but 
not kainate, receptors have been found in AD. Such evidence pre- and post-synaptic 
glutamatergic is not only involved in the pathophysiology of AD [152] but also has consequent 
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effects on neurogenesis, neurite outgrowth, synaptogenesis and neuronal cell death [153]. 
Hippocampal glutamatergic cell populations in the entorhinal cortex and subiculum are lost very 
early in AD progression, while the hippocampal GABAergic system remains relatively intact. 
Such neurodegenerative changes correlate with atrophy of astroglia, which cause disruptions in 
synaptic connectivity, misbalance in neurotransmitter homeostasis and neuronal death through 
the enhancement of glutamate-mediated neurotoxicity. Excessive overactivation of the NMDA 
receptor in particular leads to increased Ca2+, consequent free radical damage and activation of 
the proteolytic processes that contribute to cell injury or death. Thus, with the disruption of 
energy metabolism in AD, glutamate is not cleared and inappropriately released [154]. This state 
alters ionic homeostasis, meaning compromised neurons become depolarized, displacing the 
Mg2+ block from the NMDA receptor and causing excessive stimulation of glutamate receptors. 
This abnormal physiological state is thought to result in impairment in the NMDA receptor 
signaling and capacity to generate LTP, and may significantly contribute to cognitive impairment 
in AD [155, 156]. 
 The accumulation of synaptic glutamate and continual receptor stimulation may also eventual 
neuronal damage and death via excitotoxic events. Several lines of evidence have suggested a 
fundamental role for glutamate-mediated excitotoxic damage in AD. Oxidative stress and 
increased intracellular Ca2+ generated in response to Aβ have been reported to enhance 
glutamate-mediated neurotoxicity in vitro [157, 158]. Furthermore, Aβ has been demonstrated to 
significantly affect NMDA receptor-related glutamatergic signaling, equating to cognitive loss, 
in the frontal and entorhinal cortex of AD patients [159]. Glutamate transporters have also shown 
to be downregulated in AD, and Aβ can either directly or indirectly inhibit glutamate reuptake or 
 19 
enhance release [160, 161]. Such excessive glutamatergic activity may exacerbate AD pathology, 
through heightened hyperphosphorylation of tau [162].  
 
NMDA RECEPTOR COMPLEX SIGNALING DYSFUNCTION: A POINT OF 
INTERSECTION FOR DEPRESSION AND AD PATHOLOGIES 
 The apparent central role for glutamatergic-mediated transmission in late-life major 
depression and AD offers the possibility that significant overlap may occur in the signaling 
transduction mechanisms in the two disorders. As mentioned, NMDA receptor antagonists have 
been shown to possess antidepressant and antidementia properties in age and disease-related 
memory deterioration. However, despite this apparent clinical success, it is unlikely that the 
therapeutic effect lies in merely NMDA receptor blockade alone. It is thus vital to examine the 
cellular signaling pathways that are influenced by such neuroadaptational processes. A 
remarkably consistent theme in studies examining the downstream molecular events of 
antidepressant function has been the overlap with molecular events involved in neuroplasticity, 
especially synaptic plasticity [163]. Alterations in HPA axis function have been shown to 
directly influence glutamate and changes in the expression of proteins involved in glutamatergic 
signaling have been noted in animal stress models mimicking depressed-like states [164]. 
Microarray analysis has also shown significant cortical downregulation of two key glutamate 
transporters, SLC1A2 and SLC1A3, as well the expression of L-glutamate-ammonia, the enzyme 
that converts glutamate to non-toxic glycine in stress models [137]. Such changes would increase 
extracellular glutamate and activate excitotoxic processes and affect the efficiency of glutamate 
signaling.  
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 In addition to the consequences of excitotoxic damage, for example, increased intracellular 
calcium concentrations, mitochondrial damage, free radical generation, immune alterations, and 
accelerated cell ageing [165], imbalances in glutamatergic signaling may diminish the normal 
compensatory or restorative processes essential for brain repair. For example, BDNF is regulated 
through the interplay of glutamate/GABA transmission [166, 167]. BDNF is a major regulator of 
synaptic plasticity, neuronal survival and differentiation, and mediates advanced activities, such 
as learning, memory, and behavior, in addition to its established functions for cell survival [168]. 
Changes in the expression and activity of BDNF have been widely described in AD and 
depression [169] and many studies have identified BDNF as a key target of antidepressant drug 
and electroconvulsive treatment [166, 170]. Moreover, genetic polymorphisms in BDNF have 
been found to play a role the susceptibility to both late-life depression and AD. Growth factor 
signaling cascades are known to have pleiotropic effects, including cell growth, survival and 
neuroplasticity. It has been established that activation of NMDA receptors initiates such 
signaling cascades and promotes the expression of BDNF [171]. Thus it is likely that 
disturbances in the NMDA receptor complex in depression may underlie cellular plasticity and 
resilience and may contribute to glutamatergic pyramidal projection cell pathology found in 
affective circuitry areas such as the DLPFC and OFC described earlier [44, 47, 172] (Figure 1).  
 The elucidation of the molecular mechanisms underlying the rapid antidepressant effect of 
the potent NMDA antagonist ketamine has offered novel potential therapeutic targets, whose 
mode of action may prove pertinent to AD treatment. The mammalian target for rapamycin 
signaling, mTOR is an atypical Ser/Thr kinase and a central controller of protein synthesis 
required for new synaptic connections [173]. mTOR signaling is influenced by the activity of 
NMDA, metabotropic glutamate and dopaminergic receptors, as well as BDNF, and represents a 
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convergence point of several signaling pathways, including phosphoinositide-3-kinase (PI3K), 
Akt/protein kinase (Akt/PKB) [174]. A significant decrease in Akt activity has been reported in 
the prefrontal cortex of depressed suicide victims [175]. A large body of evidence has linked 
mTOR signaling with synaptic change, memory, and neurological disorders. It has recently been 
demonstrated that the antidepressant effect of ketamine and another NMDA antagonist, Ro-25-
6981, is mediated by activation of the mTOR pathway, which leads to increased synaptic 
signaling proteins and increased number and function of new synapses in the PFC in rats [176]. 
The same study showed that ketamine and Ro-25-6981 produced rapid antidepressant effects, 
which were blocked by the pre-treatment of the potent inhibitor of mTOR signaling, rapamycin 
[176]. Moreover, blockade of mTOR signaling with rapamycin completely blocked ketamine-
induced synaptogenesis [176]. The activation of mTOR and associated proteins observed after 
treatment with another NMDA receptor antagonist, MK-801, in the rat frontal cortex suggests 
that the facilitation of synaptic signaling proteins is a common feature of NMDA antagonism 
[177]. mTOR dysregulation has also been found in AD, with several signaling proteins involved 
in mTOR-regulated pathways, including Akt and mTOR itself, found to be altered in the 
postmortem brains of AD patients [178].  
 In summary, the reassessment of treatment-resistant depression, such as that found in AD, 
has led to several exciting lines of research beyond the monoaminergic hypothesis, which could 
pave the way for identification of novel biomarkers and therapeutic strategies. A substantial body 
of evidence suggests the involvement in shared NMDA-regulated signaling pathways in 
depression and AD, and may suggest an overlap of disease neurobiology. It is hoped that the 
potential therapies arising from this research will herald a breakthrough in what is becoming a 
major treatment issue within the growing global burden of AD. 
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Figure 1. Simplified hypothetical schematic diagram showing pathological cascade involved in 
depression in dementia. CRF, corticotrophic releasing factor; BDNF, brain-derived neurotrophic 
factor; CAA, cerebral amyloid angiopathy; Aβ, amyloid-β; NF, neurofibril; NFTs, 
neurofibrillary tangles; MCI, mild cognitive impairment 
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